Navigation Links
GSK Extends GeneGo License and Adds New Products

ST. JOSEPH, Mich., Feb. 5 /PRNewswire/ -- GeneGo, Inc., the leading systems biology tools company, announced today that GSK has extended their licensing agreement with GeneGo and have added additional capability. This will provide GSK researchers in Bioinformatics, R&D and clinical studies with global access to MetaCore, MapEditor and MetaBase. MetaCore is GeneGo's flagship platform for functional analysis of biological OMICs data featuring a comprehensive collection of pathway maps and network models for cellular processes and common diseases. MetaCore is used for target identification, validation, biomarker discovery and knowledge mining. GSK will also use the platform as a repository of all types of experimental data as well as resulting analyses. All of this information can be easily shared with individuals or groups. MetaBase is direct access to the manually curated database of pathways, networks, ontologies, medicinal chemistry and diseases covering human, mouse and rat. MapEditor is a powerful research tool for creating interactive custom maps which amalgamate MetaBase knowledge content with proprietary information and data.

"We have a good working relationship with GSK developing new products such as our pay as you go 1-2-3 Workflow," said Julie Bryant, GeneGo's VP of Business development. "We will continue to work closely developing new functionality, tools and content for GSK."

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery(TM) platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo's flagship product, MetaCore 4.5(TM), assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug 4.5(TM) is designed for prediction of human metabolism, toxicity and biological effects for novel small molecules compounds. MetaBase(TM) represents the knowledge base for MetaCore. For more information, please visit the company's web site at

MetaCore(TM), MetaBase(TM), MetaDrug(TM), MetaLink(TM), MetaDiscovery(TM), MetaTox(TM), MetaMiner(TM) and 1-2-3 Workflow(TM) are trademarks of GeneGo, Inc.

SOURCE GeneGo, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Extends Tender Offer for Ventana
2. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
3. Organon Extends MetaCore License and Adds MetaLink
4. NASA Extends Cooperative Agreement With NSBRI
5. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
6. Roche Extends Tender Offer for Ventana
7. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform
8. GeneGo Integrates With Cytoscape
9. Utrecht University Licenses MetaDrug From GeneGo for Drug Innovation
10. GeneGo Enters Multi-Year Agreement With Bristol Myers Squibb for Access to GeneGo Software Suite and Databases
11. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
Post Your Comments:
(Date:11/30/2015)... and MAGDEBURG, Germany , November ... NeuroRehabilitation (ECNR) in Vienna, Austria ... European Congress of NeuroRehabilitation (ECNR) in Vienna, ... --> NovaVision, a wholly owned subsidiary of Vycor Medical, ... version of its Internet-delivered NovaVision Therapy Suite at the ...
(Date:11/30/2015)... and PETACH TIKVAH, Israel , ... BCLI ), a leading developer of adult stem ... subsidiary, Brainstorm Cell Therapeutics Ltd., has been awarded an additional ... Office of the Chief Scientist (OCS). This grant, the second ... for 2015 activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... ... November 27, 2015 , ... Pittcon is pleased ... technical presentations offered in symposia, oral sessions, workshops, awards, and posters. The ... range of applications such as, but not limited to, biotechnology, biomedical, drug discovery, ...
(Date:11/26/2015)... England , November 26, 2015 ... an innovative medical device company specializing in imaging technologies, announced ... the European Commission as part of the Horizon 2020 European ... to carry out a large-scale clinical trial in breast cancer. ...      (Logo: , --> ...
Breaking Biology Technology:
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
(Date:11/9/2015)... DUBLIN , Nov. 09, 2015 /PRNewswire/ ... announced the addition of the "Global ... to their offering. --> ... "Global Law Enforcement Biometrics Market 2015-2019" ... Research and Markets ( ) ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
Breaking Biology News(10 mins):